Oncolytics Biotech
ONCY
36 hedge funds and large institutions have $1.46M invested in Oncolytics Biotech in 2020 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 5 closing their positions.
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
3% more funds holding
Funds holding: 35 → 36 (+1)
0.16% less ownership
Funds ownership: 2.11% → 1.95% (-0.16%)
6% less capital invested
Capital invested by funds: $1.56M → $1.46M (-$98.7K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
+$111K |
| 2 |
Creative Planning
Overland Park,
Kansas
|
+$110K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$29.7K |
| 4 |
Renaissance Technologies
New York
|
+$23.1K |
| 5 |
JP Morgan Chase
New York
|
+$20.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FC
Financial Consulate
Hunt Valley,
Maryland
|
-$78K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
-$64.2K |
| 3 |
BBVA
Banco Bilbao Vizcaya Argentaria
Madrid,
Spain
|
-$56K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$47.4K |
| 5 |
Two Sigma Advisers
New York
|
-$44.2K |
ONCY Hedge Fund Activity: Q3 2020 in Review
36 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q3 2020, worth a combined $1.46M — down 6.3% from $1.56M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ONCY positions and 5 closed out — a net gain of 1 holder — while 8 added to existing stakes and 7 trimmed.
The largest buyer was International Assets Investment Management, adding an estimated $111K. The largest seller was Financial Consulate, exiting entirely with an estimated $78K sold.
- 36 institutional investors held Oncolytics Biotech (ONCY) as of Q3 2020, up from 35 in Q2 2020.
- Funds reported $1.46M of Oncolytics Biotech stock for Q3 2020, down 6.3% quarter-over-quarter.
- 6 funds opened new Oncolytics Biotech positions in Q3 2020 and 5 closed out, a net change of +1 holder.
- The largest Oncolytics Biotech buyer in Q3 2020 was International Assets Investment Management, an estimated $111K added.
- The largest Oncolytics Biotech seller in Q3 2020 was Financial Consulate, an estimated $78K sold.
Based on aggregated 13F filings for Q3 2020.